Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer

This pilot phase 2 study evaluate the effectiveness and safety of pembrolizumab and lenvatinib in patients with anaplastic thyroid cancer. Patients with anaplastic thyroid cancer who are treatment-naive (BRAF-negative) and who were previously treated with chemptherapy or targeted therapy are scheduled to undergo pembrolizumab and lenvatinib and evaluate the outcomes according to the primary and secondary endpoints.

Trial Details

NCT ID

NCT06374602

Phase

PHASE2

Sponsor

Saint Petersburg State University, Russia

Status

RECRUITING

Cancer Type

Thyroid Cancer

Interventions

Pembrolizumab + Lenvatinib

Locations (sample)

Saint Petersburg, Russia|59.93863,30.31413

Key Eligibility Criteria

immunohistochemically verified anaplastic thyroid cancer that is not eligible to R0-R1 surgery;
age ≥ 18 years;
functional status of ECOG 0-2;
adequate function of internal organs and bone marrow;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Thyroid Cancer Trials on Trialify →